Idiopathic Pulmonary Fibrosis Treatment Market: Global Market Size, Forecast, Insights, and Competitive Landscape
The global idiopathic pulmonary fibrosis treatment market is expected to grow at a CAGR of around 8.0% during 2023-2030. This report on global idiopathic pulmonary fibrosis treatment market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. The report presents a clear picture of the global idiopathic pulmonary fibrosis treatment market by segmenting the market based on drug class, end-user, and region. Also, detailed profiles of companies operating in the idiopathic pulmonary fibrosis treatment market are provided in this report. We believe that this report will aid the professionals and industry stakeholders in making informed decision.
Market Drivers
Base Year: 2022
Historical Period: 2018-2022
Forecast Period: 2023-2030
Market by Drug Class
Market Drivers
- Increasing Prevalence of Fibrotic Diseases
- Rising Geriatric Population
- Lack of Awareness
- Availability of Proper Treatment
Base Year: 2022
Historical Period: 2018-2022
Forecast Period: 2023-2030
Market by Drug Class
- MAPK Inhibitors
- Tyrosine Inhibitors
- Autotaxin Inhibitors
- Hospitals
- Long-term Care Facilities
- Others
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- Turkey
- Iran
- United Arab Emirates
- Rest of Middle East & Africa
1. PREFACE
1.1 Objective
1.2 Target Audience & Key Offerings
1.3 Report’s Scope
1.4 Research Methodology
1.4.1 Phase I
1.4.2 Phase II
1.4.3 Phase III
1.5 Assumptions
2. KEY INSIGHTS
3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET
3.1. Introduction
3.2. Market Drives
3.3. Market Challenges
4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS
4.1. Market Portraiture
4.2. Market Size
4.3. Market Forecast
4.4. Impact of COVID-19
5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY DRUG CLASS
5.1. Introduction
5.2. MAPK Inhibitors
5.3. Tyrosine Inhibitors
5.4. Autotaxin Inhibitors
6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY END USER
6.1. Introduction
6.2. Hospitals
6.3. Long-term Care Facilities
6.4. Others
7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY REGION
7.1. Introduction
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Russia
7.2.7. Netherlands
7.2.8. Rest of the Europe
7.3. North America
7.3.1. United States
7.3.2. Canada
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. South Korea
7.4.5. Australia
7.4.6. Indonesia
7.4.7. Rest of the Asia Pacific
7.5. Latin America
7.5.1. Mexico
7.5.2. Brazil
7.5.3. Argentina
7.5.4. Rest of Latin America
7.6. Middle East & Africa
7.6.1. Saudi Arabia
7.6.2. Turkey
7.6.3. Iran
7.6.4. United Arab Emirates
7.6.5. Rest of Middle East & Africa
8. SWOT ANALYSIS
9. PORTER’S FIVE FORCES
10. MARKET VALUE CHAIN ANALYSIS
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Company Profiles
11.2.1. AdAlta Pty Ltd.
11.2.2. Angion Biomedica Corp.
11.2.3. Boehringer Ingelheim International GmbH
11.2.4. Bristol-Myers Squibb Company
11.2.5. Cipla Inc.
11.2.6. F. Hoffmann-La Roche AG (Roche Holding AG)
11.2.7. Fibrogen Inc.
11.2.8. Galapagos NV
11.2.9. Liminal BioSciences Inc.
11.2.10. Medicinova Inc.
11.2.11. Merck & Co. Inc.
11.2.12. Novartis AG
11.2.13. Vectura Group Plc.
1.1 Objective
1.2 Target Audience & Key Offerings
1.3 Report’s Scope
1.4 Research Methodology
1.4.1 Phase I
1.4.2 Phase II
1.4.3 Phase III
1.5 Assumptions
2. KEY INSIGHTS
3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET
3.1. Introduction
3.2. Market Drives
3.3. Market Challenges
4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET ANALYSIS
4.1. Market Portraiture
4.2. Market Size
4.3. Market Forecast
4.4. Impact of COVID-19
5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY DRUG CLASS
5.1. Introduction
5.2. MAPK Inhibitors
5.3. Tyrosine Inhibitors
5.4. Autotaxin Inhibitors
6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY END USER
6.1. Introduction
6.2. Hospitals
6.3. Long-term Care Facilities
6.4. Others
7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET BY REGION
7.1. Introduction
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Russia
7.2.7. Netherlands
7.2.8. Rest of the Europe
7.3. North America
7.3.1. United States
7.3.2. Canada
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. South Korea
7.4.5. Australia
7.4.6. Indonesia
7.4.7. Rest of the Asia Pacific
7.5. Latin America
7.5.1. Mexico
7.5.2. Brazil
7.5.3. Argentina
7.5.4. Rest of Latin America
7.6. Middle East & Africa
7.6.1. Saudi Arabia
7.6.2. Turkey
7.6.3. Iran
7.6.4. United Arab Emirates
7.6.5. Rest of Middle East & Africa
8. SWOT ANALYSIS
9. PORTER’S FIVE FORCES
10. MARKET VALUE CHAIN ANALYSIS
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Company Profiles
11.2.1. AdAlta Pty Ltd.
11.2.2. Angion Biomedica Corp.
11.2.3. Boehringer Ingelheim International GmbH
11.2.4. Bristol-Myers Squibb Company
11.2.5. Cipla Inc.
11.2.6. F. Hoffmann-La Roche AG (Roche Holding AG)
11.2.7. Fibrogen Inc.
11.2.8. Galapagos NV
11.2.9. Liminal BioSciences Inc.
11.2.10. Medicinova Inc.
11.2.11. Merck & Co. Inc.
11.2.12. Novartis AG
11.2.13. Vectura Group Plc.
LIST OF TABLES
Table 1: Global Idiopathic Pulmonary Fibrosis Treatment Market Portraiture
Table 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in US$ Million), 2022 & 2030
Table 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in US$ Million), 2022 & 2030
Table 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in US$ Million), 2022 & 2030
Table 5: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 6: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 7: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 8: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 9: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 10: List of Key Players
Table 1: Global Idiopathic Pulmonary Fibrosis Treatment Market Portraiture
Table 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in US$ Million), 2022 & 2030
Table 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in US$ Million), 2022 & 2030
Table 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in US$ Million), 2022 & 2030
Table 5: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 6: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 7: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 8: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 9: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in US$ Million), 2022 & 2030
Table 10: List of Key Players
LIST OF FIGURES
Figure 1: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class, 2022
Figure 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User, 2022
Figure 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region, 2022
Figure 5: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 6: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in %), 2022 & 2030
Figure 7: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 8: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 9: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 10: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 11: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 12: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 13: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in %), 2022 & 2030
Figure 14: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 15: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 16: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 17: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 18: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 19: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 20: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in %), 2022 & 2030
Figure 21: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 22: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 23: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 24: Germany Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 25: United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 26: France Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 27: Italy Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 28: Spain Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 29: Russia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 30: Netherlands Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 31: Rest of Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 32: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 33: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 34: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 35: United States Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 36: Canada Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 37: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 38: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 39: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 40: China Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 41: Japan Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 42: India Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 43: South Korea Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 44: Australia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 45: Indonesia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 46: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 47: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 48: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 49: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 50: Mexico Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 51: Brazil Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 52: Argentina Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 53: Rest of Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 54: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 55: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 56: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 57: Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 58: Turkey Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 59: Iran Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 60: UAE Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 61: Rest of Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 62: Market Value Chain
Figure 1: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 2: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class, 2022
Figure 3: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User, 2022
Figure 4: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region, 2022
Figure 5: Global Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 6: Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class (in %), 2022 & 2030
Figure 7: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 8: Global MAPK Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 9: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 10: Global Tyrosine Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 11: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 12: Global Autotaxin Inhibitors Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 13: Global Idiopathic Pulmonary Fibrosis Treatment Market by End User (in %), 2022 & 2030
Figure 14: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 15: Global Hospitals Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 16: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 17: Global Long-term Care Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 18: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 19: Global Other Facilities Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 20: Global Idiopathic Pulmonary Fibrosis Treatment Market by Region (in %), 2022 & 2030
Figure 21: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 22: Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 23: Europe Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 24: Germany Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 25: United Kingdom Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 26: France Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 27: Italy Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 28: Spain Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 29: Russia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 30: Netherlands Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 31: Rest of Europe Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 32: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 33: North America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 34: North America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 35: United States Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 36: Canada Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 37: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 38: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 39: Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 40: China Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 41: Japan Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 42: India Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 43: South Korea Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 44: Australia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 45: Indonesia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 46: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 47: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 48: Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 49: Latin America Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 50: Mexico Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 51: Brazil Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 52: Argentina Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 53: Rest of Latin America Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 54: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2022
Figure 55: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2023-2030
Figure 56: Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market by Country (in %), 2022 & 2030
Figure 57: Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 58: Turkey Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 59: Iran Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 60: UAE Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 61: Rest of Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market (in US$ Million), 2018-2030
Figure 62: Market Value Chain
